COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media
Abstract
:1. Introduction
2. Material and Methods
2.1. Data Collection
2.2. Data Analysis
3. Results
3.1. Rush for COVID-19 Vaccine
“I cannot trust a vaccine produced this quick. So many steps skipped.”
“I cannot trust a vaccine produced this quick. So many steps skipped and we don’t know if long-term side effects are a thing.”
“It’s come out so fast that it’s clearly politically and profit-motivated.”
“Has this vaccine undertaken rigorous testing with a large sample group?”
“The real question is how many people did they test this vaccine on.”
3.2. Long-Term Effect
“It is not being an anti-vaxxer; it’s called making a sensible educated decision. Vaccines usually take 7 years to develop. I’m not willing to be a guinea pig for pharmaceutical companies”
“How can anyone trust a vaccine without any long-term trials?”
“Vaccines usually take a decade or more of research. No one knows what the side effects may be of an expedited vaccine. I’m pro-vaccination but not for one that was pushed through research.”
“As soon as it’s proven safe with longer-term trials, I’d be perfectly happy to take it, but with the long-term side effects being so unknown, I’d be very nervous to.”
“It takes years for side effects to appear, and they could very well be worse than the sickness.”
“I’m trying to get pregnant, has it been tested to ensure that it will not affect my reproductive organs or compromise future pregnancy. The vaccine is just too new. We don’t know the long-term side effects.”
“I would wait 6 months to see how it affects people.”
“If I was to get vaccinated it’s going to be in five years. Many things could go wrong such as late side effects. When people get a high dose of radiation, they don’t get cancer straight away it takes time.”
“There are no credible data to prove the long-term safety and efficacy of this vaccine. At this stage, it’s still experimental, even if all regulatory approvals are in place.”
3.3. Duration of Protection
“My only concern really... how long is it in your body? Is it like flu vaccine and you need a new one each year?
“But how long is the vaccine effective?”
“Does the constant mutation impact its efficacy?”
“The virus is a mutating one, as previously said; how will a vaccine be of any use anyhow? The virus will mutate, become stronger & still infect people.”
“This is not possible because the virus has mutated into different strains.”
3.4. Vaccine Compositions
“What is in the vaccine?”
“We need to know what the components are that make up this particular vaccine given the stigma and hesitation from so many citizens of the World.”
“Is it likely to contain Mercury and other heavy metals? What’s the risk as with other vaccines of other complications”
“There’s aborted babies in this new vaccine... ”
“Anything that would have aborted foetal tissue in it I’m not putting in my body.”
“The vaccine probably contains mercury and other chemicals including raw eggs.”
3.5. New mRNA Vaccine Technology
“An mRNA vaccine a year ago was only “theoretical”; definitely hasn’t been around long enough to have any long-term studies.”
“What about the conspiracy theory that it’s a way of injecting nano chips...?”
“This vaccine is part of their agenda. Nobody wants a microchip.”
“The new vaccine for COVID-19 will be the first of its kind EVER. It will be an mRNA vaccine which will literally alter your DNA. “
3.6. Preference for Natural Immunity
“Nature immunity, artificial immunity comes with risk.”
“Natural immunity is 99.9% effective.”
“My immune system is 99.4% effective…”
3.7. Vaccine Effectiveness versus Survival Rate
“It’s not worth risking taking it. It’s worse than coronavirus itself.”
“They (young people) don’t need it as it doesn’t affect the young.”
“99.6% survival rate sounds like the opposite of deadly in my opinion.”
“You need a vaccine for something that you have a 1% chance of getting? And a 99% chance of full recovery?”
“A vaccine for a virus that has a death rate of 1%? I’ll take my chances.”
“95% effective for a virus that kills at 0.5%.”
“If it’s 95% effective, what are the consequences to the remaining 5%? Is it side effects or death? Honestly, it has to be 100%. 95% is not yet perfect because in 100 people 5 will still be get (the infection)..?”
“How long can this take to be verified as safe? 94.6% isn’t safe to me.”
“A 94.5% effective, brand new vaccine with unknown long-term effects versus risking getting a virus that has a 99.96% survival rate and then building up natural immunity anyway. I’ll take my chances.”
3.8. Lack of Scientific Evidence
“According to company data...We still don’t know enough about potential side effects, but I do understand the urgency.”
“Don’t believe it until peer-reviewed”
“No scientist has peer-reviewed the study, and there were no people with any illnesses included or any older people; just the healthiest people were in this study.”
“According to company data” which means that it’s not a reliable source.”
“When the stakes are so high and the profit is exorbitant, human life is of no value!”
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO. [Homepage on the Internet]. Draft Landscape of COVID-19 Candidate Vaccines. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccine (accessed on 23 January 2021).
- Peretti-Watel, P.; Seror, V.; Cortaredona, S.; Launay, O.; Raude, J.; Verger, P.; Fressard, L.; Beck, F.; Legleye, S.; L’Haridon, O.; et al. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect. Dis. 2020, 20, 769–770. [Google Scholar] [CrossRef]
- Wong, L.P.; Alias, H.; Wong, P.F.; Lee, H.Y.; AbuBakar, S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum. Vaccines Immunother. 2020, 16, 2204–2214. [Google Scholar] [CrossRef]
- Harapan, H.; Wagner, A.L.; Yufika, A.; Winardi, W.; Anwar, S.; Gan, A.K.; Setiawan, A.M.; Rajamoorthy, Y.; Sofyan, H.; Mudatsir, M. Acceptance of a COVID-19 vaccine in southeast Asia: A cross-sectional study in Indonesia. Front. Public Health 2020, 8, 381. [Google Scholar] [CrossRef]
- Lin, Y.; Hu, Z.; Zhao, Q.; Alias, H.; Danaee, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl. Trop. Med. 2020, 14, e0008961. [Google Scholar] [CrossRef]
- Malik, A.A.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine 2020, 26, 100495. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef] [PubMed]
- Cao, S. [Homepage on the Internet]. Here Are All the Side Effects of Every Top COVID-19 Vaccine in US. Observer. Available online: https://observer.com/2020/10/vaccine-side-effects-moderna-pfizer-johnson-astrazeneca/ (accessed on 24 January 2021).
- Farr, C.; Lovelace, B., Jr. [Homepage on the Internet]. Coronavirus Vaccine Trial Participants Report Day-Long Exhaustion, Fever and Headaches—But Say It’s Worth It. CNBC. Available online: https://www.cnbc.com/2020/10/01/coronavirus-vaccine-trial-participants-exhaustion-fever-headaches.html (accessed on 24 January 2021).
- Heidt, A. [Homepage on the Internet]. COVID-19 Vaccine Trial Pauses After Adverse Reaction. The Scientist. Available online: https://www.the-scientist.com/news-opinion/covid-19-vaccine-trial-pauses-after-adverse-reaction-67917 (accessed on 24 January 2021).
- Herper, M. [Homepage on the Internet]. He Experienced a Severe Reaction to Moderna’s COVID-19 Vaccine Candidate. He’s Still a Believer. STAT. Available online: https://www.statnews.com/2020/05/26/moderna-vaccine-candidate-trial-participant-severe-reaction/ (accessed on 24 January 2021).
- Taylor, N.P. [Homepage on the Internet]. AstraZeneca’s COVID-19 Vaccine Adverse Event Has NIH ‘Very Concerned’. Fierce Biotech. Available online: https://www.fiercebiotech.com/biotech/astrazeneca-s-covid-19-vaccine-adverse-event-has-nih-very-concerned (accessed on 25 January 2021).
- Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021, 21, 181–192. [Google Scholar] [CrossRef]
- Zhu, F.C.; Li, Y.H.; Guan, X.H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020, 395, 1845–1854. [Google Scholar] [CrossRef]
- Lewis, J.R. [Homepage on the Internet]. What Is Driving the Decline in People’s Willingness to Take the COVID-19 Vaccine in the United States? JAMA Health Forum. Available online: https://jamanetwork.com/channels/health-forum/fullarticle/2773320?utm_source=silverchair&utm_campaign=jama_network&utm_content=covid_weekly_highlights&utm_medium=email (accessed on 29 January 2021).
- WHO. [Homepage on the Internet]. Ten Threats to Global Health in 2019. Available online: https://www.who.int/vietnam/news/feature-stories/detail/ten-threats-to-global-health-in-2019 (accessed on 29 January 2021).
- Stolle, L.B.; Nalamasu, R.; Pergolizzi, J.V.; Varrassi, G.; Magnusson, P.; LeQuang, J.; Breve, F.; The NEMA Research Group. Fact vs fallacy: The anti-vaccine discussion reloaded. Adv. Ther. 2020, 37, 4481–4490. [Google Scholar] [CrossRef] [PubMed]
- Golder, S.; Ahmed, S.; Norman, G.; Booth, A. Attitudes toward the ethics of research using social media: A systematic review. J. Med. Internet Res. 2017, 19, e195. [Google Scholar] [CrossRef]
- Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef] [Green Version]
- Abbasi, J. COVID-19 and mRNA Vaccines—First large test for a new approach. JAMA 2020, 324, 1125–1127. [Google Scholar] [CrossRef]
- Doshi, P. Will COVID-19 vaccines save lives? Current trials aren’t designed to tell us. BMJ 2020, 371, m4037. [Google Scholar] [CrossRef] [PubMed]
- Chauhan, G.; Madou, M.J.; Kalra, S.; Chopra, V.; Ghosh, D.; Martinez-Chapa, S.O. Nanotechnology for COVID-19: Therapeutics and vaccine research. ACS Nano 2020, 14, 7760–7782. [Google Scholar] [CrossRef]
- Chung, Y.H.; Beiss, V.; Fiering, S.N.; Steinmetz, N.F. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 2020, 14, 12522–12537. [Google Scholar] [CrossRef] [PubMed]
- Le, T.T.; Andreadakis, Z.; Kumar, A.; Román, R.G.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 305–306. [Google Scholar] [CrossRef]
- Hurley, A.M.; Tadrous, M.; Miller, E.S. Thimerosal-containing vaccines and autism: A review of recent epidemiologic studies. J. Pediatr. Pharmacol. Ther. 2010, 15, 173–181. [Google Scholar] [CrossRef] [PubMed]
- Giubilini, A.; Minerva, F.; Schuklenk, U.; Savulescu, J. The ‘Ethical’COVID-19 Vaccine is the One that Preserves Lives: Religious and Moral Beliefs on the COVID-19 Vaccine. Public Health Ethics 2021, phab018. [Google Scholar] [CrossRef]
- Edwards, K.M.; Hackell, J.M. Committee on Infectious Diseases, Committee on Practice and Ambulatory Medicine. Countering vaccine hesitancy. Pediatrics 2016, 138, e20162146. [Google Scholar] [CrossRef] [Green Version]
- Edridge, A.W.; Kaczorowska, J.; Hoste, A.C.; Bakker, M.; Klein, M.; Loens, K.; Jebbink, M.F.; Matser, A.; Kinsella, C.M.; Rueda, P.; et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. 2020, 26, 1691–1693. [Google Scholar] [CrossRef] [PubMed]
- Kellam, P.; Barclay, W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J. Gen. Virol. 2020, 101, 791. [Google Scholar] [CrossRef] [PubMed]
- McAuley, A.J.; Kuiper, M.J.; Durr, P.A.; Bruce, M.P.; Barr, J.; Todd, S.; Au, G.G.; Blasdell, K.; Tachedjian, M.; Lowther, S.; et al. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. NPJ Vaccines 2020, 5, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.H.; Sibley, C.G. Attitudes toward vaccinations are becoming more polarized in New Zealand: Findings from a longitudinal survey. EClinicalMedicine 2020, 23, 100387. [Google Scholar] [CrossRef]
- Meyerowitz-Katz, G.; Merone, L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. Int. J. Infect. Dis. 2020, 101, 138–148. [Google Scholar] [CrossRef] [PubMed]
- Beaney, T.; Clarke, J.M.; Jain, V.; Golestaneh, A.K.; Lyons, G.; Salman, D.; Majeed, A. Excess mortality: The gold standard in measuring the impact of COVID-19 worldwide? J. R. Soc. Med. 2020, 113, 329–334. [Google Scholar] [CrossRef]
- Fraser, E. Long term respiratory complications of COVID-19. BMJ 2020, 370. [Google Scholar] [CrossRef] [PubMed]
- Salehi, S.; Reddy, S.; Gholamrezanezhad, A. Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): What we know and what to expect. J. Thorac. Imaging 2020, 35, W87–W89. [Google Scholar] [CrossRef]
- Yelin, D.; Wirtheim, E.; Vetter, P.; Kalil, A.C.; Bruchfeld, J.; Runold, M.; Guaraldi, G.; Mussini, C.; Gudiol, C.; Pujol, M.; et al. Long-term consequences of COVID-19: Research needs. Lancet Infect. Dis. 2020, 20, 1115–1117. [Google Scholar] [CrossRef]
- Ahmed, M.; Advani, S.; Moreira, A.; Zoretic, S.; Martinez, J.; Chorath, K.; Acosta, S.; Naqvi, R.; Burmeister-Morton, F.; Burmeister, F.; et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020, 26, 100527. [Google Scholar] [CrossRef]
- Bartsch, S.M.; O’Shea, K.J.; Ferguson, M.C.; Bottazzi, M.E.; Wedlock, P.T.; Strych, U.; McKinnell, J.A.; Siegmund, S.S.; Cox, S.N.; Hotez, P.J.; et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am. J. Prev. Med. 2020, 59, 493–503. [Google Scholar] [CrossRef]
- Badur, S.; Ota, M.; Öztürk, S.; Adegbola, R.; Dutta, A. Vaccine confidence: The keys to restoring trust. Hum. Vaccines Immunother. 2020, 16, 1007–1017. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wong, L.P.; Lin, Y.; Alias, H.; Bakar, S.A.; Zhao, Q.; Hu, Z. COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media. Healthcare 2021, 9, 1530. https://doi.org/10.3390/healthcare9111530
Wong LP, Lin Y, Alias H, Bakar SA, Zhao Q, Hu Z. COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media. Healthcare. 2021; 9(11):1530. https://doi.org/10.3390/healthcare9111530
Chicago/Turabian StyleWong, Li Ping, Yulan Lin, Haridah Alias, Sazaly Abu Bakar, Qinjian Zhao, and Zhijian Hu. 2021. "COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media" Healthcare 9, no. 11: 1530. https://doi.org/10.3390/healthcare9111530
APA StyleWong, L. P., Lin, Y., Alias, H., Bakar, S. A., Zhao, Q., & Hu, Z. (2021). COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media. Healthcare, 9(11), 1530. https://doi.org/10.3390/healthcare9111530